{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:30:38Z","timestamp":1777631438234,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,9,22]],"date-time":"2013-09-22T00:00:00Z","timestamp":1379808000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s00432-013-1529-7","type":"journal-article","created":{"date-parts":[[2013,9,21]],"date-time":"2013-09-21T14:12:43Z","timestamp":1379772763000},"page":"1985-1993","source":"Crossref","is-referenced-by-count":9,"title":["Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome\/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study"],"prefix":"10.1007","volume":"139","author":[{"given":"Andreas","family":"Hochhaus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp D.","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Erben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey","family":"McCulloch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Novick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,22]]},"reference":[{"issue":"9","key":"1529_CR1","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","volume":"92","author":"M Baccarani","year":"2007","unstructured":"Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S et al (2007) The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92(9):1173\u20131179","journal-title":"Haematologica"},{"issue":"10","key":"1529_CR2","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.exphem.2008.04.017","volume":"36","author":"C Baumgartner","year":"2008","unstructured":"Baumgartner C, Gleixner KV, Peter B, Ferenc V, Gruze A, Remsing Rix LL et al (2008) Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Exp Hematol 36(10):1244\u20131253","journal-title":"Exp Hematol"},{"issue":"1","key":"1529_CR3","first-page":"M11","volume":"1551","author":"E Buchdunger","year":"2001","unstructured":"Buchdunger E, Matter A, Druker BJ (2001) Bcr-abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta 1551(1):M11\u2013M18","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"1529_CR4","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.leukres.2008.12.001","volume":"33","author":"JH Butterfield","year":"2009","unstructured":"Butterfield JH (2009) Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome. Leuk Res 33(8):1127\u20131129","journal-title":"Leuk Res"},{"issue":"2","key":"1529_CR5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/j.seminhematol.2012.01.001","volume":"49","author":"JH Butterfield","year":"2012","unstructured":"Butterfield JH, Weiler CR (2012) Treatment of hypereosinophilic syndromes\u2014the first 100\u00a0years. Semin Hematol 49(2):182\u2013191","journal-title":"Semin Hematol"},{"issue":"13","key":"1529_CR6","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","volume":"348","author":"J Cools","year":"2003","unstructured":"Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al (2003a) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348(13):1201\u20131214","journal-title":"N Engl J Med"},{"issue":"5","key":"1529_CR7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(03)00108-9","volume":"3","author":"J Cools","year":"2003","unstructured":"Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM et al (2003b) PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 3(5):459\u2013469","journal-title":"Cancer Cell"},{"issue":"3","key":"1529_CR8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.drup.2005.04.005","volume":"8","author":"J Cools","year":"2005","unstructured":"Cools J, Maertens C, Marynen P (2005) Resistance to tyrosine kinase inhibitors: calling on extra forces. Drug Resist Updat 8(3):119\u2013129","journal-title":"Drug Resist Updat"},{"issue":"21","key":"1529_CR9","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1182\/blood-2010-11-318949","volume":"117","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Hochhaus A, le Coutre PD, Rosti G, Pinilla-Ibarz J, Jabbour E et al (2011) Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood 117(21):5600\u20135606","journal-title":"Blood"},{"issue":"1","key":"1529_CR10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaci.2010.03.035","volume":"126","author":"MM Crane","year":"2010","unstructured":"Crane MM, Chang CM, Kobayashi MG, Weller PF (2010) Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol 126(1):179\u2013181","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1529_CR11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000140631","volume":"119","author":"NC Cross","year":"2008","unstructured":"Cross NC, Reiter A (2008) Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol 119(4):199\u2013206","journal-title":"Acta Haematol"},{"issue":"10","key":"1529_CR12","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood-2010-05-286757","volume":"117","author":"C Elling","year":"2011","unstructured":"Elling C, Erben P, Walz C, Frickenhaus M, Schemionek M, Stehling M et al (2011) Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 117(10):2935\u20132943","journal-title":"Blood"},{"issue":"5","key":"1529_CR13","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/leu.2011.355","volume":"26","author":"FJ Giles","year":"2012","unstructured":"Giles FJ, Kantarjian HM, le Coutre PD, Baccarani M, Mahon FX, Blakesley RE et al (2012) Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 26(5):959\u2013962","journal-title":"Leukemia"},{"issue":"1","key":"1529_CR14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG et al (2013) Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 27(1):107\u2013112","journal-title":"Leukemia"},{"issue":"9","key":"1529_CR15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/ajh.23293","volume":"87","author":"J Gotlib","year":"2012","unstructured":"Gotlib J (2012) World health organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87(9):903\u2013914","journal-title":"Am J Hematol"},{"issue":"11","key":"1529_CR16","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2008.287","volume":"22","author":"J Gotlib","year":"2008","unstructured":"Gotlib J, Cools J (2008) Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 22(11):1999\u20132010","journal-title":"Leukemia"},{"issue":"8","key":"1529_CR17","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2003-06-1824","volume":"103","author":"J Gotlib","year":"2004","unstructured":"Gotlib J, Cools J, Malone JM III, Schrier SL, Gilliland DG, Coutre SE (2004) The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 103(8):2879\u20132891","journal-title":"Blood"},{"key":"1529_CR18","doi-asserted-by":"crossref","unstructured":"Gotlib J, DeAngelo DJ, George TI, Corless CL, Linder A, Langford C et al (2010) KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial. Blood 116(21): abstract 316","DOI":"10.1182\/blood.V116.21.316.316"},{"key":"1529_CR19","doi-asserted-by":"crossref","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O et al (2012) KIT inhibitor midostaurin in patients with advanced systemic mastocytosis: Results of a planned interim analysis of the global CPKC412D2201 trial. Blood 120(Suppl): abstract 799","DOI":"10.1182\/blood.V120.21.799.799"},{"issue":"2","key":"1529_CR20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/hon.919","volume":"28","author":"G Helbig","year":"2010","unstructured":"Helbig G, Moskwa A, Hus M, Piszcz J, Swiderska A, Urbanowicz A et al (2010) Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript\u2013results of Polish multicentre study. Hematol Oncol 28(2):93\u201397","journal-title":"Hematol Oncol"},{"issue":"6","key":"1529_CR21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ajh.23193","volume":"87","author":"G Helbig","year":"2012","unstructured":"Helbig G, Soja A, Bartkowska-Chrobok A, Kyrcz-Krzemien S (2012) Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation. Am J Hematol 87(6):643\u2013645","journal-title":"Am J Hematol"},{"issue":"8","key":"1529_CR22","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/j.leukres.2010.02.024","volume":"34","author":"T Ikezoe","year":"2010","unstructured":"Ikezoe T, Togitani K, Tasaka T, Nishioka C, Yokoyama A (2010) Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib. Leuk Res 34(8):e200\u2013e201","journal-title":"Leuk Res"},{"issue":"24","key":"1529_CR23","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, Bhalla K, O\u2019Brien S, Wassmann B et al (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354(24):2542\u20132551","journal-title":"N Engl J Med"},{"issue":"10","key":"1529_CR24","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F et al (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110(10):3540\u20133546","journal-title":"Blood"},{"issue":"8","key":"1529_CR25","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","volume":"103","author":"AD Klion","year":"2004","unstructured":"Klion AD, Law MA, Noel P, Kim YJ, Haverty TP, Nutman TB (2004) Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 103(8):2939\u20132941","journal-title":"Blood"},{"issue":"6","key":"1529_CR26","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/leu.2011.323","volume":"26","author":"PD Coutre le","year":"2012","unstructured":"le Coutre PD, Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, Blakesley R et al (2012) Nilotinib in patients with Ph\u00a0+\u00a0chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 26(6):1189\u20131194","journal-title":"Leukemia"},{"issue":"4","key":"1529_CR27","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2006-02-004457","volume":"108","author":"E Lierman","year":"2006","unstructured":"Lierman E, Folens C, Stover EH, Mentens N, Van Miegroet H, Scheers W et al (2006) Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 108(4):1374\u20131376","journal-title":"Blood"},{"issue":"7","key":"1529_CR28","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/leu.2012.8","volume":"26","author":"E Lierman","year":"2012","unstructured":"Lierman E, Smits S, Cools J, Dewaele B, Debiec-Rychter M, Vandenberghe P (2012) Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia 26(7):1693\u20131695","journal-title":"Leukemia"},{"key":"1529_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2326-9-1","volume":"9","author":"G Loules","year":"2009","unstructured":"Loules G, Kalala F, Giannakoulas N, Papadakis E, Matsouka P, Speletas M (2009) FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia. BMC Blood Disord 9:1","journal-title":"BMC Blood Disord"},{"issue":"19","key":"1529_CR30","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1016\/j.bmc.2010.08.026","volume":"18","author":"PW Manley","year":"2010","unstructured":"Manley PW, Stiefl N, Cowan-Jacob SW, Kaufman S, Mestan J, Wartmann M et al (2010) Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem 18(19):6977\u20136986","journal-title":"Bioorg Med Chem"},{"issue":"5","key":"1529_CR31","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2141.2008.07294.x","volume":"143","author":"G Metzgeroth","year":"2008","unstructured":"Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C et al (2008) Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 143(5):707\u2013715","journal-title":"Br J Haematol"},{"issue":"1","key":"1529_CR32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/leu.2011.181","volume":"26","author":"G Metzgeroth","year":"2012","unstructured":"Metzgeroth G, Erben P, Martin H, Mousset S, Teichmann M, Walz C et al (2012) Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia 26(1):162\u2013164","journal-title":"Leukemia"},{"key":"1529_CR33","unstructured":"National Cancer Institute (2006) Common terminology criteria for adverse events (CTCAE), version 3.0"},{"key":"1529_CR34","unstructured":"Novartis Pharmaceuticals Corporation (January 2012) Gleevec [package insert]"},{"key":"1529_CR35","unstructured":"Novartis Pharmaceuticals Corporation (May 2012) Tasigna [package insert]"},{"issue":"Suppl 1","key":"1529_CR36","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.leukres.2003.10.006","volume":"28","author":"A Pardanani","year":"2004","unstructured":"Pardanani A, Tefferi A (2004) Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Leuk Res 28(Suppl 1):S47\u2013S52","journal-title":"Leuk Res"},{"issue":"5","key":"1529_CR37","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.leu.2403722","volume":"19","author":"C Roche-Lestienne","year":"2005","unstructured":"Roche-Lestienne C, Lepers S, Soenen-Cornu V, Kahn JE, Lai JL, Hachulla E et al (2005) Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 19(5):792\u2013798","journal-title":"Leukemia"},{"issue":"12","key":"1529_CR38","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","volume":"358","author":"ME Rothenberg","year":"2008","unstructured":"Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU et al (2008) Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358(12):1215\u20131228","journal-title":"N Engl J Med"},{"issue":"9","key":"1529_CR39","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3324\/haematol.2009.010421","volume":"94","author":"F Roufosse","year":"2009","unstructured":"Roufosse F (2009) Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations. Haematologica 94(9):1188\u20131193","journal-title":"Haematologica"},{"key":"1529_CR40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1750-1172-2-37","volume":"2","author":"FE Roufosse","year":"2007","unstructured":"Roufosse FE, Goldman M, Cogan E (2007) Hypereosinophilic syndromes. Orphanet J Rare Dis 2:37","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"1529_CR41","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.11248","volume":"92","author":"S Soverini","year":"2007","unstructured":"Soverini S, Iacobucci I, Baccarani M, Martinelli G (2007) Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica 92(4):437\u2013439","journal-title":"Haematologica"},{"issue":"9","key":"1529_CR42","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2005-05-1932","volume":"106","author":"EH Stover","year":"2005","unstructured":"Stover EH, Chen J, Lee BH, Cools J, McDowell E, Adelsperger J et al (2005) The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFR\u03b2 and FIP1L1-PDGFR\u03b1 in vitro and in vivo. Blood 106(9):3206\u20133213","journal-title":"Blood"},{"issue":"1","key":"1529_CR43","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.leukres.2010.08.004","volume":"35","author":"E Tabouret","year":"2011","unstructured":"Tabouret E, Charbonnier A, Mozziconacci MJ, Ivanov V (2011) Low-dose nilotinib can maintain complete molecular remissions in FIP1L1\/PDGFRA-positive hypereosinophilic syndrome. Leuk Res 35(1):136","journal-title":"Leuk Res"},{"issue":"12","key":"1529_CR44","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/WOX.0b013e31827f4192","volume":"5","author":"P Valent","year":"2012","unstructured":"Valent P, Klion AD, Rosenwasser LJ, Arock M, Bochner BS, Butterfield JH et al (2012) ICON: eosinophil disorders. World Allergy Organ J 5(12):174\u2013181","journal-title":"World Allergy Organ J"},{"issue":"4","key":"1529_CR45","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.leu.2403313","volume":"18","author":"P Vandenberghe","year":"2004","unstructured":"Vandenberghe P, Wlodarska I, Michaux L, Zachee P, Boogaerts M, Vanstraelen D et al (2004) Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 18(4):734\u2013742","journal-title":"Leukemia"},{"issue":"2","key":"1529_CR46","first-page":"26","volume":"1","author":"S Verstovsek","year":"2007","unstructured":"Verstovsek S (2007) New hematological indications for imatinib. Eur Oncol Dis 1(2):26\u201328","journal-title":"Eur Oncol Dis"},{"issue":"12","key":"1529_CR47","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.leukres.2006.03.012","volume":"30","author":"S Verstovsek","year":"2006","unstructured":"Verstovsek S, Giles FJ, Quintas-Cardama A, Manshouri T, Huynh L, Manley P et al (2006) Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res 30(12):1499\u20131505","journal-title":"Leuk Res"},{"issue":"1","key":"1529_CR48","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/1078-0432.CCR-08-1302","volume":"15","author":"S Verstovsek","year":"2009","unstructured":"Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A et al (2009) Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res 15(1):368\u2013373","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1529_CR49","doi-asserted-by":"crossref","first-page":"e30567","DOI":"10.1371\/journal.pone.0030567","volume":"7","author":"D Wicklein","year":"2012","unstructured":"Wicklein D, Ramos Leal N, Salamon J, Thamer M, Herrmann H, Valent P et al (2012) Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model. PLoS One 7(2):e30567","journal-title":"PLoS One"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-013-1529-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-013-1529-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-013-1529-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T01:24:07Z","timestamp":1715995447000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-013-1529-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,22]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1529"],"URL":"https:\/\/doi.org\/10.1007\/s00432-013-1529-7","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,22]]}}}